How can we ensure that all communities are represented in Alzheimer’s and related dementias research and have access to the latest treatments and interventions? Dr. Carl Hill, the chief diversity, equity and inclusion (DEI) officer for the Alzheimer's Association, joins the podcast to delve into the significance of representation, diversity, equity, equality and inclusion within Alzheimer's disease research. He discusses the challenges of underrepresentation in clinical trials, the importance of community-based participatory research (CBPR) and the social determinants of health that influence Alzheimer's risk.

Guest: Carl V. Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer's Association

Learn more about the Alzheimer’s Association’s effort in DEI from their inaugural DEI report.

Learn more about race-related topics in Alzheimer’s disease from the Alzheimer’s Association International Conference (AAIC) 2022 here, including a study on the impact of racism on the brain and findings on racial disparities in health equity and resources in Black and Brown communities.

Listen to Dr. Hill’s past episodes of Dementia Matters, “Scientific Importance Of Diversity In Alzheimer’s Disease Research,” and, “Battling Health Disparities In Aging Research And Care,” on our website.

Learn more about Dr. Hill in his bio on the Alzheimer’s Association’s website.

Find transcripts and more at our website.

Email Dementia Matters: [email protected]

Follow us on Facebook and Twitter.

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.